Department of Pathology, Ankara Yildirim Beyazit University, Ankara, Turkey.
Department of Pathology, Ankara City Hospital, Ankara, Turkey.
Diagn Cytopathol. 2021 Aug;49(8):928-937. doi: 10.1002/dc.24768. Epub 2021 May 19.
The Milan system reporting salivary gland cytopathology (MSRSGC) is a tiered classification scheme that is based on risk stratification. The aim of the current study was to assess the risk of malignancy (ROM) and risk of neoplasia (RON) in each of the diagnostic categories proposed by the MSRSGC.
A retrospective analysis and categorization according to the MSRSGC was made of salivary gland fine needle aspirations (FNA) performed from January 2007 to December 2017. The FNA cytology results were correlated with subsequent histological follow-up.
A total of 578 FNAs were evaluated and histopathology was available for 198 cases (34.2%). The RON and ROM for individual diagnostic categories were: Non-diagnostic: 52.2% to 13%, non-neoplastic: 21.4% to 10.7%, atypia of undetermined significance: 74% to 22.2%, benign neoplasm: 100% to 1.1%, salivary gland neoplasm of uncertain malignant potential: 93.3% to 53.3%, suspicious for malignancy (SFM): 100% to 100%, and malignant: 100% to 100%. A diagnosis of 'SFM' or 'malignant' with FNA cytology carried a 100% risk for malignancy, while a diagnosis of "non-neoplastic," "benign neoplasm" reduced the probability of malignancy to 3.4%.
The MSRSGC is useful for the management of salivary gland lesions as it can successfully differentiate between benign and malignant cases. It will bring uniformity in salivary gland FNA cytology reporting across various institutions globally.
米兰系统报告唾液腺细胞病理学(MSRSGC)是一种基于风险分层的分层分类方案。本研究旨在评估 MSRSGC 提出的每个诊断类别中的恶性肿瘤风险(ROM)和肿瘤风险(RON)。
对 2007 年 1 月至 2017 年 12 月期间进行的唾液腺细针抽吸术(FNA)进行回顾性分析和 MSRSGC 分类。将 FNA 细胞学结果与随后的组织学随访相关联。
共评估了 578 例 FNA,其中 198 例(34.2%)有组织病理学结果。各个诊断类别的 RON 和 ROM 分别为:非诊断性:52.2%至 13%,非肿瘤性:21.4%至 10.7%,意义未明的非典型性:74%至 22.2%,良性肿瘤:100%至 1.1%,唾液腺恶性潜能未定肿瘤:93.3%至 53.3%,可疑恶性(SFM):100%至 100%,恶性:100%至 100%。FNA 细胞学诊断为“可疑恶性”或“恶性”时,恶性肿瘤的风险为 100%,而诊断为“非肿瘤性”、“良性肿瘤”时,恶性肿瘤的可能性降低至 3.4%。
MSRSGC 可成功地区分良性和恶性病例,因此可用于唾液腺病变的管理。它将在全球范围内为各个机构的唾液腺 FNA 细胞学报告带来一致性。